Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: a consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology

被引：0

作者：

José Trigo

Mónica García-Cosío

Almudena García-Castaño

Montserrat Gomà

Ricard Mesia-Nin

Elena Ruiz-Bravo

Ainara Soria-Rivas

Paola Castillo

Irene Braña-García

Margarita Alberola-Ferranti

机构：

[1] HC Marbella International Hospital,

[2] Spanish Society of Medical Oncology (SEOM),undefined

[3] Ramón y Cajal University Hospital,undefined

[4] Spanish Society of Pathological Anatomy (SEAP),undefined

[5] Marqués de Valdecilla University Hospital,undefined

[6] Spanish Society of Medical Oncology (SEOM),undefined

[7] Bellvitge University Hospital,undefined

[8] Spanish Society of Pathological Anatomy (SEAP),undefined

[9] Catalan Institute of Oncology (ICO),undefined

[10] Badalona Applied Research Group in Oncology,undefined

[11] Germans Trias i Pujol Research Institute,undefined

[12] Spanish Society of Medical Oncology (SEOM),undefined

[13] La Paz University Hospital,undefined

[14] Spanish Society of Pathological Anatomy (SEAP),undefined

[15] Ramón y Cajal University Hospital,undefined

[16] Spanish Society of Medical Oncology (SEOM),undefined

[17] Clínic de Barcelona Hospital,undefined

[18] Spanish Society of Pathological Anatomy (SEAP),undefined

[19] Vall d’Hebron University Hospital,undefined

[20] Spanish Society of Medical Oncology (SEOM),undefined

[21] Vall d’Hebron University Hospital,undefined

[22] Spanish Society of Pathological Anatomy (SEAP),undefined

来源：

Clinical and Translational Oncology | 2022年 / 24卷

关键词：

PD-L1; Prognosis; Individualized therapy; Response to treatment; Epstein Barr virus; Human papillomavirus;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

The treatment of head and neck and salivary gland tumours is complicated and evolves constantly. Prognostic and predictive indicators of response to treatment are enormously valuable for designing individualized therapies, which justifies their research and validation. Some biomarkers, such as p16, Epstein–Barr virus, PD-L1, androgen receptors and HER-2, are already used routinely in clinical practice. These biomarkers, along with other markers that are currently under development, and the massively parallel sequencing of genes, ensure future advances in the treatment of these neoplasms. In this consensus, a group of experts in the diagnosis and treatment of tumours of the head and neck and salivary glands were selected by the Spanish Society of Pathology (Sociedad Española de Anatomía Patológica—SEAP) and the Spanish Society of Medical Oncology (Sociedad Española de Oncología Médica—SEOM) to evaluate the currently available information and propose a series of recommendations to optimize the determination and daily clinical use of biomarkers.

引用

页码：1890 / 1902

页数：12

共 50 条

[31] Guidelines for biomarker testing in gastroenteropancreatic neuroendocrine neoplasms: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Garcia-Carbonero, R.
Vilardell, F.
Jimenez-Fonseca, P.
Gonzalez-Campora, R.
Gonzalez, E.
Cuatrecasas, M.
Capdevila, J.
Aranda, I.
Barriuso, J.
Matias-Guiu, X.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2014, 16 (03): : 243 - 256
[32] Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Garcia-Alfonso, P.
Garcia-Foncillas, J.
Salazar, R.
Perez-Segura, P.
Garcia-Carbonero, R.
Musulen-Palet, E.
Cuatrecasas, M.
Landolfi, S.
Ramon y Cajal, S.
Navarro, S.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (04): : 264 - 273
[33] Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
P. García-Alfonso
J. García-Foncillas
R. Salazar
P. Pérez-Segura
R. García-Carbonero
E. Musulén-Palet
M. Cuatrecasas
S. Landolfi
S. Ramón y Cajal
S. Navarro
Clinical and Translational Oncology, 2015, 17 : 264 - 273
[34] Guidelines for biomarker testing in gastroenteropancreatic neuroendocrine neoplasms: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
R. García-Carbonero
F. Vilardell
P. Jiménez-Fonseca
R. González-Campora
E. González
M. Cuatrecasas
J. Capdevila
I. Aranda
J. Barriuso
X. Matías-Guiu
Clinical and Translational Oncology, 2014, 16 : 243 - 256
[35] Recommendations for radiological diagnosis and assessment of treatment response in lung cancer: a national consensus statement by the Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology
de Castro, J.
Cobo, M.
Isla, D.
Puente, J.
Reguart, N.
Cabeza, B.
Gayete, A.
Sanchez, M.
Torres, M. I.
Ferreiros, J.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (01): : 11 - 23
[36] Recommendations forradiological diagnosis and assessment of treatment response in lung cancer: A national consensus statement by the Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology
Ferreiros, J.
Cabeza, B.
Gayete, A.
Sanchez, M.
Torres, M. I.
Cobo, M.
Isla, D.
Puente, J.
Reguart, N.
de Castro, J.
RADIOLOGIA, 2015, 57 (01): : 66 - 78
[37] Recommendations for radiological diagnosis and assessment of treatment response in lung cancer: a national consensus statement by the Spanish Society of Medical Radiology and the Spanish Society of Medical Oncology
J. de Castro
M. Cobo
D. Isla
J. Puente
N. Reguart
B. Cabeza
A. Gayete
M. Sánchez
M. I. Torres
J. Ferreirós
Clinical and Translational Oncology, 2015, 17 : 11 - 23
[38] Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)
Joan Albanell
Xavier Andreu
María José Calasanz
Ángel Concha
José María Corominas
Tomás García-Caballero
José Antonio López
Fernando López-Ríos
Santiago Ramón y Cajal
Francisco J. Vera-Sempere
Ramón Colomer
Miguel Martín
Emilio Alba
Antonio González-Martín
Antonio Llombart
Ana Lluch
José Palacios
Clinical and Translational Oncology, 2009, 11 : 363 - 375
[39] Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Felip, E.
Concha, A.
de Castro, J.
Gomez-Roman, J.
Garrido, P.
Ramirez, J.
Isla, D.
Sanz, J.
Paz-Ares, L.
Lopez-Rios, F.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (02): : 103 - 112
[40] Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
E. Felip
Á. Concha
J. de Castro
J. Gómez-Román
P. Garrido
J. Ramírez
D. Isla
J. Sanz
L. Paz-Ares
F. López-Ríos
Clinical and Translational Oncology, 2015, 17 : 103 - 112

← 1 2 3 4 5 →